Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2015

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 1 X post from an account with 1,035 followers.

Tumor response from durvalumab and tremelimumab treatment in patients with advanced non-small cel... https://t.co/EeAR9erkI0 #jitc

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.